MRI引导聚焦超声局灶治疗中危前列腺癌患者:一项2b期多中心研究
这项单臂多中心2b期研究在美国8个中心纳入101例50岁以上、单侧、MRI可见的2级或3级中危前列腺癌患者,接受MRI引导聚焦超声局灶治疗;24个月时89例中78例(88%,95%CI 79-94)治疗区域无2级及以上癌,无4级或5级治疗相关不良事件,仅1例3级不良事件(尿路感染),无治疗相关死亡。
要点
- 24个月时78/89例(88%,95%CI 79-94)治疗区域无2级及以上前列腺癌。
- 仅报告1例3级不良事件(尿路感染),无4级或5级治疗相关不良事件,无治疗相关死亡。
- 作者认为结果支持对特定患者采用局灶治疗,并用于对比试验以确定保留组织的方案能否长期延迟或免除根治性全腺体治疗。
核心结论
- 24个月活检结果显示MRI引导聚焦超声局灶治疗安全且有效治疗2级或3级前列腺癌。
- 作者认为结果支持对特定患者采用局灶治疗,并用于对比试验以确定保留组织的方案能否长期延迟或免除根治性全腺体治疗。
研究设计与样本
- 单臂、多中心、2b期研究,在美国8个医疗中心开展。
- 2017年5月4日至2018年12月21日评估194例患者资格,治疗101例患者。
- 纳入50岁及以上、单侧、MRI可见、原发、中危、既往未治疗的前列腺腺癌患者(前列腺特异性抗原≤20 ng/mL,2级或3级;肿瘤分类≤T2),经联合活检(联合MRI靶向与系统活检)确认。
- MRI引导聚焦超声能量序贯滴定为足以组织消融的温度(约60-70°C),递送至索引病灶及计划5 mm或以上的正常组织边缘,术中使用实时磁共振测温监测。
- 共同主要结局为肿瘤学结局(6个月和24个月联合活检时治疗区域无2级及以上癌;当24个月活检数据不可用且6个月时治疗区域已出现2级及以上癌时,将6个月活检结果纳入最终分析)和安全性(至24个月的不良事件),分析所有入组患者。
主要发现
- 中位年龄63岁(IQR 58-67),中位前列腺特异性抗原浓度5.7 ng/mL(IQR 4.2-7.5)。
- 大多数癌为2级(101例中79例[78%])。
- 24个月时,89例中78例(88%[95%CI 79-94])治疗区域无2级及以上前列腺癌证据。
- 未报告4级或5级治疗相关不良事件,仅报告1例3级不良事件(尿路感染)。
- 无治疗相关死亡。
临床怎么用
- 作者认为结果支持对特定患者采用局灶治疗,并用于对比试验以确定保留组织的方案能否长期延迟或免除根治性全腺体治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. METHODS: In this single-arm, multicentre, phase 2b study conducted at eight health-care centres in the USA, we recruited men aged 50 years and older with unilateral, MRI-visible, primary, intermediate-risk, previously untreated prostate adenocarcinoma (prostate-specific antigen ≤20 ng/mL, grade group 2 or 3; tumour classification ≤T2) confirmed on combined biopsy (combining MRI-targeted and systematic biopsies). MRI-guided focused ultrasound energy, sequentially titrated to temperatures sufficient for tissue ablation (about 60-70°C), was delivered to the index lesion and a planned margin of 5 mm or more of normal tissue, using real-time magnetic resonance thermometry for intraoperative monitoring. Co-primary outcomes were oncological outcomes (absence of grade group 2 and higher cancer in the treated area at 6-month and 24-month combined biopsy; when 24-month biopsy data were not available and grade group 2 or higher cancer had occurred in the treated area at 6 months, the 6-month biopsy results were included in the final analysis) and safety (adverse events up to 24 months) in all patients enrolled in the study. This study is registered with ClinicalTrials.gov, NCT01657942, and is no longer recruiting. FINDINGS: Between May 4, 2017, and Dec 21, 2018, we assessed 194 patients for eligibility and treated 101 patients with MRI-guided focused ultrasound. Median age was 63 years (IQR 58-67) and median concentration of prostate-specific antigen was 5·7 ng/mL (IQR 4·2-7·5). Most cancers were grade group 2 (79 [78%] of 101). At 24 months, 78 (88% [95% CI 79-94]) of 89 men had no evidence of grade group 2 or higher prostate cancer in the treated area. No grade 4 or grade 5 treatment-related adverse events were reported, and only one grade 3 adverse event (urinary tract infection) was reported. There were no treatment-related deaths. INTERPRETATION: 24-month biopsy outcomes show that MRI-guided focused ultrasound focal therapy is safe and effectively treats grade group 2 or 3 prostate cancer. These results support focal therapy for select patients and its use in comparative trials to determine if a tissue-preserving approach is effective in delaying or eliminating the need for radical whole-gland treatment in the long term. FUNDING: Insightec and the National Cancer Institute.
引用
- Ehdaie B, Tempany CM, Holland F, et al. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol. 2022. PMID: 35714666. doi:10.1016/S1470-2045(22)00251-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。